Inovio Pharmaceuticals (INO) Gains from Investment Securities (2019 - 2026)

Inovio Pharmaceuticals has reported Gains from Investment Securities for 8 years, with the latest figure at -$4.1 million in Q1 2026.

• Quarterly Gains from Investment Securities fell 11.44% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.7 million (up 575.97% YoY) and the FY2025 annual result came in at -$493231.0, up 74.11% from the prior year.
• Gains from Investment Securities declined to -$4.1 million in Q1 2026 per INO's latest filing, from $397657.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $22.5 million in Q3 2025 and troughed at -$4.1 million in Q1 2026.
• A 5-year average of $534189.1 and a median of -$785568.5 in 2022 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities plunged 63135.92% in 2023, then jumped 163.48% in 2025.
• Over 5 years, Gains from Investment Securities stood at -$2.8 million in 2022, then surged by 65.56% to -$952113.0 in 2023, then surged by 34.21% to -$626410.0 in 2024, then surged by 163.48% to $397657.0 in 2025, then plunged by 1140.52% to -$4.1 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$4.1 million, $397657.0, and $22.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.